We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

BRUKER

BRUKER offers high-performance scientific instruments and high-value analytical and diagnostic solutions that enable ... read more Featured Products: More products

Download Mobile App




New Functionalities Introduced for Microbial High-Throughput MALDI-TOF MS Platform

By LabMedica International staff writers
Posted on 19 May 2014
Beta-lactamase antibiotic resistance testing, productivity software, and efficiency accessories are now available for the microbial MALDI Biotyper. More...


The MALDI Biotyper for microbial identification, based on MALDI-TOF mass spectrometry, is widely used in industrial and research-use-only (RUO) applications, and in its in vitro diagnostics (IVD) versions, CE- and FDA-cleared, is changing the paradigm in clinical microbial diagnostics and research. MALDI Biotyper covers a broad range of about 2,300 species with more than 5,600 well-characterized microbial isolates. It uses reliable and quick proteomic fingerprinting of unique species-specific patterns, requires minimal sample preparation, and offers low consumables cost.

Due to the modular design of the MALDI Biotyper software, the system can be configured according to the specific needs of each laboratory: the basic identification functionality is now available in versions for clinical routine IVD laboratories, for industrial applications, and for RUO purposes. Industrial and research customers can additionally configure functionality by adding various new or expanded RUO software modules or hardware accessories.

The MBT STAR-BL (Beta Lactamase) module is part of the new MBT STAR assay family for selective testing of antibiotic resistance (STAR), and enables patented functional beta-lactamase testing for selected antibiotics, without the need of labeling by probes or antibodies. Although currently for RUO, Bruker is gathering feedback from infectious disease researchers on its performance and, due to strong demand for this type of resistance information, clinical IVD versions are being planned.

For industrial and RUO applications, data integrity topics like user management, audit trail, and data archiving are of special importance. For these customers, Bruker now offers the new MBT Compliance Assistance Module to support 21 CFR Part 11 requirements.

MBT Translator and MBT Integrator modules provide functionality to connect and integrated data generated with the MALDI Biotyper into laboratory information systems (LIS).

The MBT Galaxy reduces the manual workload during preparation of sample target plates and also introduces significant quality control steps, like controlled reagent droplet size, controlled drying atmosphere, and controlled quality of the matrix preparation. This bench-top automation device standardizes the preparation of samples with quality controls for reagent additions. The MBT Galaxy eliminates the need for manual reagent pipetting, reducing repetitive motions and labor costs required for target preparation. The MBT Galaxy is equipped with on-board barcode reading to connect directly to the MALDI Biotyper server.

The MBT Pilot supports the light-guided preparation of target plates. With the MBT Satellite software it allows for a paperless and barcode-tracked workflow with full traceability. Its ergonomic shape guides users during the preparation of plates, reducing the possibility of specimen transfer errors.

“We have been working with Bruker´s MALDI Biotyper system in our network of microbiology laboratories for several years and we are very pleased with the analytical performance,” said Dr. Ulrich Eigner, Head of Study Department at Limbach Laboratory (Heidelberg, Germany).

Products of the MALDI Biotyper family are available in the US FDA-cleared MALDI Biotyper CA System version, in the IVD-CE version cleared according to EU directive EC/98/79, and in a research-use-only (RUO) version. The MALDI Biotyper also has medical device registrations in numerous other countries.

Related Links:

Bruker



New
Gold Member
Latex Test
SLE-Latex Test
Serological Pipet Controller
PIPETBOY GENIUS
New
Silver Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
New
PlGF Test
Quidel Triage PlGF Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.